Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection
- PMID: 8300199
- PMCID: PMC186119
- DOI: 10.1128/iai.62.2.384-389.1994
Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection
Abstract
This study investigated whether differences in fecal and serum antitoxin A antibody levels may account for the duration of Clostridium difficile-associated diarrhea (CDAD) and the occurrence of relapses. By an enzyme linked-immunosorbent assay, we tested 40 patients with CDAD including 25 patients without immunodeficiency and 15 patients receiving antineoplastic drugs. Two hundred eighty serum samples and 80 normal stool samples were investigated as controls. In nonimmunocompromised patients, serum immunoglobulin (IgG) and fecal IgA antitoxin A antibody titers were significantly higher in patients who suffered a single episode (n = 21) than in those with relapsing CDAD (n = 4) whose titers were at control levels. Of these 25 patients, eight suffered from diarrhea which lasted for more than 2 weeks. These patients had significantly lower serum- and feces-specific antibody levels than the others who presented symptoms of shorter duration. In cytostatic-treated patients, antitoxin A antibody levels were similar to controls, but relapses occurred in a single case. These data suggest an association between a defective humoral response to toxin A and a more severe form of C. difficile infection. They also indicate that other host-related factors control the severity of CDAD and remain to be elucidated.
Similar articles
-
Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease.Clin Gastroenterol Hepatol. 2007 Jun;5(6):707-13. doi: 10.1016/j.cgh.2007.02.025. Clin Gastroenterol Hepatol. 2007. PMID: 17544998
-
Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea.Clin Gastroenterol Hepatol. 2007 Aug;5(8):964-8. doi: 10.1016/j.cgh.2007.04.018. Epub 2007 Jul 6. Clin Gastroenterol Hepatol. 2007. PMID: 17618838
-
IgG antibody response to toxins A and B in patients with Clostridium difficile infection.Clin Vaccine Immunol. 2012 Sep;19(9):1552-4. doi: 10.1128/CVI.00210-12. Epub 2012 Jul 11. Clin Vaccine Immunol. 2012. PMID: 22787196 Free PMC article.
-
Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.Toxins (Basel). 2010 May;2(5):998-1018. doi: 10.3390/toxins2050998. Epub 2010 May 7. Toxins (Basel). 2010. PMID: 22069622 Free PMC article. Review.
-
Clostridium difficile infection in non-HIV-immunocompromised patients and in HIV-infected patients.Curr Gastroenterol Rep. 2011 Aug;13(4):344-50. doi: 10.1007/s11894-011-0196-6. Curr Gastroenterol Rep. 2011. PMID: 21541693 Review.
Cited by
-
Measurement of faecal immunoglobulin a levels in young children.J Clin Lab Anal. 2004;18(3):195-9. doi: 10.1002/jcla.20022. J Clin Lab Anal. 2004. PMID: 15103685 Free PMC article.
-
Treatment of refractory and recurrent Clostridium difficile infection.Nat Rev Gastroenterol Hepatol. 2011 Jun;8(6):330-9. doi: 10.1038/nrgastro.2011.59. Epub 2011 Apr 19. Nat Rev Gastroenterol Hepatol. 2011. PMID: 21502971 Review.
-
The combination of recombinant and non-recombinant Bacillus subtilis spore display technology for presentation of antigen and adjuvant on single spore.Microb Cell Fact. 2017 Sep 12;16(1):151. doi: 10.1186/s12934-017-0765-y. Microb Cell Fact. 2017. PMID: 28899372 Free PMC article.
-
Bacteria That Cause Enteric Diseases Stimulate Distinct Humoral Immune Responses.Front Immunol. 2020 Sep 16;11:565648. doi: 10.3389/fimmu.2020.565648. eCollection 2020. Front Immunol. 2020. PMID: 33042146 Free PMC article. Review.
-
Immune response against Clostridioides difficile and translation to therapy.Therap Adv Gastroenterol. 2021 May 7;14:17562848211014817. doi: 10.1177/17562848211014817. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 33995585 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous